Person profile

Public information reviewed

Jennifer Jarrett

Role

President and Chief Executive Officer at Damora Therapeutics, Inc. (NASDAQ: DMRA)

Board role

Director · Sagimet Biosciences Inc. (NASDAQ: SGMT)

Board role

Director · Zura Bio Ltd (NASDAQ: ZURA)

Board role

President, Chief Executive Officer and Director · Damora Therapeutics, Inc. (NASDAQ: DMRA)

Sagimet Biosciences Inc. (NASDAQ: SGMT)

Director · Current mandate

Director · Executive
FollowSave PDF
More
Reports & analysis (Check report directory)Alpha Eval
Evidence records
10
Profile ownership
Not yet claimed
Record reviewed
Sep 6, 2026
View evidence

Structured intelligence coverage

Structured records are temporarily unavailable. The published profile and its source ledger remain accessible.

Identity checks do not refresh the age of governance evidence. Open a record for its source date and review state.

Profile

Identity, professional record and current appointments.

Overview

Professional record at a glance

A concise summary of information supported by the cited public sources. Missing information is treated as unknown, not as a negative finding.

Current roles
43 current organizations shown on this profile
Board positions
33 supported by public sources, 0 supplied by the profile owner
Committee roles
3Roles supported by the sources cited on this profile
Qualifications
Not establishedNo qualification is currently confirmed by the cited sources

Professional narrative

About

Chief Operating Officer of Arcus Biosciences since October 2020. Previously VP of Corporate Development and Capital Markets at Uber Technologies. Spent 20 years in investment banking at Citigroup, Credit Suisse and DLJ, running west coast life sciences practice. Holds MBA from Stanford.

Sources are shown with the information they support.

Current roles

Appointments & responsibilities

Executive appointments

Board appointments

Governance

Board appointments, committee responsibilities and disclosed relationships.

Committee appointments across companies · Temporarily unavailable

Structured records for this section are unavailable. This does not establish that no records exist. Published profile sources remain in Evidence & History.

Board and advisory record

Board service

Sources are shown with each role, education record, or credential.

Director

Sagimet Biosciences Inc.

2024-01-01 · current

Confirmed by public sourceView source

Director

Zura Bio Ltd

2023-01-01 · current

Confirmed by public sourceView source

President, Chief Executive Officer and Director

Damora Therapeutics, Inc.

Current · start date not disclosed

Confirmed by public sourceView source

Connections

Explore the roles, education and affiliations published in this record.

Damora Therapeutics, Inc.

Open Damora Therapeutics, Inc. profile →

President and Chief Executive Officer at Damora Therapeutics, Inc.

Start not stated → End not stated

current · source reported

Observed: 2026-09-25

President, Chief Executive Officer and Director at Damora Therapeutics, Inc.

Start not stated → End not stated

current · source reported

Observed: 2026-09-25

Damora Therapeutic…Damora Therapeutics, Inc.Sagimet Bioscience…Sagimet Biosciences Inc.Zura Bio LtdZura Bio LtdJennifer Jarrett

Dashed lines mark past roles. Select a connection to see its dates and sources.

Relationship map

Connected through the public record

Direct relationships from verified facts and published résumé records. Private connections are excluded.

Direct public links only

Only published affiliations are shown here. Private relationships require authorized access.

Experience

Career history, education, credentials and public contributions.

Published record

Featured coverage

Selected publications and public sources used to establish this profile. Inclusion records provenance; it is not an endorsement.

Source 1 · Sec FilingGLTO DEF 14A executive officersSupports AI and ML experience, Cybersecurity experience, Executive company, Executive title, Technology background.Open sourceSource 2 · Sec FilingSGMT DEF 14A director slateSupports Board role, Committee assignments.Open sourceSource 3 · Sec FilingZURA DEF 14A director slateSupports AI and ML experience, Board role, Committee assignments, Executive company, Executive title, Cybersecurity experience, Technology background.Open source

Basis

Identifiers, sources, dates and record limitations.

Identifiers

Alpha ID
alpha:person:jennifer-jarrett-2
Record version
public-0

Published evidence records

10 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.

  1. GLTO DEF 14A executive officers

    sec filing · Source published: Apr 29, 2026 · Retrieved: Jul 28, 2026

    Supports 5 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Galecto, Inc. · Claim reviewed: Jul 28, 2026
    • Executive title: Executive title: President, Chief Executive Officer and Director · Claim reviewed: Jul 28, 2026
    • Technology background: Technology background: not identified in the cited filing · Claim reviewed: May 16, 2026

  2. DMRA DEF 14A executive officers

    sec filing · Source published: Apr 29, 2026 · Retrieved: May 16, 2026

    Supports 2 claims
    • Executive company: Executive at Galecto, Inc. · Claim reviewed: Jul 28, 2026
    • Executive title: Executive title: President, Chief Executive Officer and Director · Claim reviewed: Jul 28, 2026

  3. Open source

    sec def 14a · Source published: Apr 29, 2026 · Retrieved: Sep 6, 2026

    Supports 3 claims
    • Professional Role: President and Chief Executive Officer at Damora Therapeutics, Inc. · Claim reviewed: Sep 6, 2026
    • Professional Role: President, Chief Executive Officer and Director at Damora Therapeutics, Inc. · Claim reviewed: Sep 6, 2026
    • Executive title: Executive title: President and Chief Executive Officer · Claim reviewed: Sep 6, 2026

  4. SGMT DEF 14A director slate

    sec filing · Source published: Apr 21, 2026 · Retrieved: May 16, 2026

    Supports 2 claims
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: Committee assignments: Audit · Claim reviewed: May 16, 2026

  5. Open source

    sec proxy · Source published: Apr 21, 2026 · Retrieved: Apr 24, 2026

    Supports 1 claim
    • Professional Role: Director at Sagimet Biosciences Inc. · Claim reviewed: Sep 6, 2026

  6. ZURA DEF 14A director slate

    sec filing · Source published: Apr 23, 2025 · Retrieved: May 16, 2026

    Supports 7 claims
    • AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Board role: Board role: Director · Claim reviewed: May 16, 2026
    • Committee assignments: Committee assignments: Compensation, Nominating/Governance · Claim reviewed: May 16, 2026
    • Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: May 16, 2026
    • Executive company: Executive at Arcus Biosciences, Inc. · Claim reviewed: May 16, 2026
    • Executive title: Executive title: Chief Operating Officer · Claim reviewed: May 16, 2026
    • Technology background: Technology background reported in filings · Claim reviewed: May 16, 2026

  7. Open source

    sec proxy · Source published: Apr 23, 2025 · Retrieved: Apr 28, 2026

    Supports 1 claim
    • Professional Role: Director at Zura Bio Ltd · Claim reviewed: Sep 6, 2026

  8. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Sagimet Biosciences Inc. · Claim reviewed: Sep 6, 2026

  9. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Zura Bio Ltd · Claim reviewed: Sep 6, 2026

  10. Open source

    public source · Source published: Date unavailable · Retrieved: Date unavailable

    Supports 1 claim
    • Board membership: Serves on the board of Damora Therapeutics, Inc. · Claim reviewed: Sep 6, 2026

Sources

Sources and published information

Each item links to the public source used to support it. When sources disagree, the item is clearly marked for review.

AI and ML experience · CorroboratedAI and ML experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 28, 2026

Board membership · Source reportedServes on the board of Damora Therapeutics, Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of Sagimet Biosciences Inc.1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board membership · Source reportedServes on the board of Zura Bio Ltd1 source
Verification
Source reported
Confidence
Not stated
Last reviewed
Not stated
Board role · CorroboratedBoard role: DirectorSupported by 2 public records2 sources
Verification
Corroborated
Confidence
92%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Committee assignments · Source reportedCommittee assignments: Audit1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Committee assignments · Source reportedCommittee assignments: Compensation, Nominating/Governance1 source
Verification
Source reported
Confidence
88%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Cybersecurity experience · CorroboratedCybersecurity experience: not identified in the cited filingSupported by 2 public records2 sources
Verification
Corroborated
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 28, 2026

Executive company · Source reportedExecutive at Arcus Biosciences, Inc.1 source
Verification
Source reported
Confidence
85%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive company · CorroboratedExecutive at Galecto, Inc.Supported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
Jul 28, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 28, 2026

Executive title · Source reportedExecutive title: Chief Operating Officer1 source
Verification
Source reported
Confidence
85%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

Executive title · Source reportedExecutive title: President and Chief Executive Officer1 source
Verification
Source reported
Confidence
95%
Last reviewed
Sep 6, 2026
Executive title · CorroboratedExecutive title: President, Chief Executive Officer and DirectorSupported by 2 public records2 sources
Verification
Corroborated
Confidence
94%
Last reviewed
Jul 28, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 28, 2026

Technology background · Under reviewTechnology background: not identified in the cited filing1 source
Verification
Under review
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 28, 2026

Technology background · Under reviewTechnology background reported in filings1 source
Verification
Under review
Confidence
72%
Last reviewed
May 16, 2026
  • SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

View all sources10 records
  1. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed Jul 28, 2026

    Supports: AI and ML experience · Cybersecurity experience · Executive company · Executive title · Technology background

  2. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: Executive company · Executive title

  3. https://www.sec.gov/Archives/edgar/data/1800315/000119312526191429/dmra-20260429.htm

    Sec Def 14a · Tier not stated · Reviewed Sep 6, 2026

    Supports: President and Chief Executive Officer at Damora Therapeutics, Inc. (NASDAQ: DMRA) · President, Chief Executive Officer and Director at Damora Therapeutics, Inc. (NASDAQ: DMRA) · Executive title

  4. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: Board role · Committee assignments

  5. https://www.sec.gov/Archives/edgar/data/1400118/000110465926046006/tm261563-1_def14a.htm

    Sec Proxy · Tier not stated · Reviewed Apr 24, 2026

    Supports: Director at Sagimet Biosciences Inc. (NASDAQ: SGMT)

  6. SEC EDGAR

    Sec Filing · Tier 3 · Reviewed May 16, 2026

    Supports: AI and ML experience · Board role · Committee assignments · Executive company · Executive title · Cybersecurity experience · Technology background

  7. https://www.sec.gov/Archives/edgar/data/1855644/000110465925038042/tm2512764-2_def14a.htm

    Sec Proxy · Tier not stated · Reviewed Apr 28, 2026

    Supports: Director at Zura Bio Ltd (NASDAQ: ZURA)

  8. https://www.sec.gov/Archives/edgar/data/1400118/000110465926046006/tm261563-1_def14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  9. https://www.sec.gov/Archives/edgar/data/1855644/000110465925038042/tm2512764-2_def14a.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership

  10. https://www.sec.gov/Archives/edgar/data/1800315/000119312526191429/dmra-20260429.htm

    Public Source · Tier not stated · Reviewed Not stated

    Supports: Board membership